Analytical Data
-
基因名
SCN9A
- Application
-
别名
ETHA; GEFSP7; hNE Na; hNE-Na; hNENa; NE NA; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Scn9a; SCN9A_HUMAN; Sodium channel protein type 9 subunit alpha; Sodium channel protein type IX subunit alpha; Sodium channel voltage gated type IX alpha; Sodium channel voltage gated type IX alpha polypeptide; Sodium channel voltage gated type IX alpha subunit; Voltage gated sodium channel alpha subunit Nav1.7; Voltage gated sodium channel subunit alpha Nav1; Voltage-gated sodium channel subunit alpha Nav1.7
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q15858
-
表达区间
269-339 aa
-
氨基酸序列
GNLKHKCFRNSLENNETLESIMNTLESEEDFRKYFYYLEGSKDALLCGFSTDSGQCPEGYTCVKIGRNPDY
-
分子量
33.55 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SCN9A encodes the voltage-gated sodium channel NaV1.7, which plays a crucial role in the generation and propagation of action potentials in neurons, particularly in nociceptive pathways associated with pain perception. Mutations in the SCN9A gene have been linked to various pain disorders, including congenital insensitivity to pain and inherited erythromelalgia, highlighting its significance in pain modulation. The study of SCN9A recombinant proteins enables researchers to explore the biophysical properties of NaV1.7, including ion selectivity, gating mechanics, and interaction with pharmacological agents. Understanding these characteristics is essential for developing targeted therapies for pain management. Furthermore, the recombinant production of SCN9A may allow for the characterization of the effects of specific mutations observed in patients, aiding in the elucidation of pain mechanisms at a molecular level. The advancement in techniques such as cryo-electron microscopy and electrophysiological recording enhances the ability to study the structure and function of NaV1.7, providing insights into its role in pathophysiology. Overall, SCN9A recombinant protein research is vital for advancing our understanding of pain biology and paving the way for novel analgesic strategies.
